| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918793 | Radiotherapy and Oncology | 2013 | 6 Pages |
Abstract
SABR for synchronous MPLC achieves a lesion control rate of 84% after 2Â years, with limited toxicity. SABR should be considered when patients with lung cancer present with a synchronous second lesion and no nodal involvement.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gwendolyn H.M.J. Griffioen, Frank J. Lagerwaard, Cornelis J.A. Haasbeek, Egbert F. Smit, Ben J. Slotman, Suresh Senan,